Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
5.17
+0.01 (0.19%)
At close: May 21, 2026, 4:00 PM EDT
5.23
+0.06 (1.16%)
After-hours: May 21, 2026, 5:04 PM EDT

Cadrenal Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23
Selling, General & Admin
8.849.356.753.55
Depreciation & Amortization Expenses
00.0100
Research & Development
3.24.14.214.08
Total Operating Expenses
12.0513.4610.967.63
Operating Income
-12.05-13.46-10.96-7.63
Interest Income
0.160.220.310.25
Interest Expense
----0.02
Other Non-Operating Income (Expense)
----0.96
Total Non-Operating Income (Expense)
0.160.220.31-0.72
Pretax Income
-11.89-13.24-10.65-8.36
Net Income
-11.89-13.24-10.65-8.36
Net Income to Common
-11.89-13.24-10.65-8.36
Shares Outstanding (Basic)
2211
Shares Outstanding (Diluted)
2211
Shares Change (YoY)
64.49%63.48%35.59%-
EPS (Basic)
-5.63-6.64-8.73-9.29
EPS (Diluted)
-5.63-6.64-8.73-9.29
Shares Outstanding
2.512.341.780.87
Free Cash Flow
-10.96-12.61-7.36-3.53
Free Cash Flow Per Share
-5.13-6.32-6.04-3.93
EBITDA
-12.05-13.45-10.96-7.63
EBIT
-12.05-13.46-10.96-7.63
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q